VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy
Journal of Clinical Oncology · 13.10.2026
DOI: 10.1200/jco-26-00992 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, online erschienen am 13.10.2026. Verfasst von Andrew T Kuykendall und 27 weiteren Autor:innen. Beteiligte Einrichtung: Moffitt Cancer Center, Tampa, FL. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Purpose
Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by erythrocytosis. Rusfertide is a subcutaneous, injectable, hepcidin mimetic peptide that suppresses erythrocytosis. The phase III VERIFY trial evaluated the efficacy and safety of rusfertide in phlebotomy-dependent patients with PV and poorly controlled hematocrit.
Methods
In VERIFY Part 1a (32 weeks), patients requiring frequent phlebotomy were randomly assigned (1:1, double-blind) to receive rusfertide or placebo with or without cytoreductive therapy. The primary efficacy end point was clinical response (absence of phlebotomy eligibility; weeks 20-32). Key secondary end points (baseline to week 32) included mean number of phlebotomies, proportion of patients who maintained hematocrit
Autor:innen und Institutionen
- Moffitt Cancer Center, Tampa, FL.
- Princess Margaret Malignancy Centre, Toronto, ON, Canada.
- University of Michigan, Ann Arbor, MI.
- Oregon Health & Science University, Portland, OR.
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
- Hospital Universitario Ramón y Cajal Instituto Ramón y Cajal de Investigación Sanitaria, Universidad de Alcalá, Madrid, Spain.
ORCID-Profile: Andrew T Kuykendall, Aniket Bankar, Alessandro Lucchesi, Valentín García-Gutiérrez, Jiri Mayer, Abdulraheem Yacoub, Harinder Gill, Joseph M Scandura, Marina Kremyanskaya, David M Ross, Francesca Palandri, Maria Laura Fox, Alessandro Maria Vannucchi, Tamanna Haque, Jean-Jacques Kiladjian, Naveen Pemmaraju
Zitieren
APA
Kuykendall, A. T., Bankar, A., Pettit, K. M., Shatzel, J., Lucchesi, A., García-Gutiérrez, V., Mayer, J., Yacoub, A., Gill, H., Sasca, D., Scandura, J. M., Kremyanskaya, M., Ross, D. M., Palandri, F., Fox, M. L., Vannucchi, A. M., Haque, T., Koschmieder, S., Kiladjian, J. J., …, & VERIFY Investigators (2026). VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00992
Vancouver
Kuykendall AT, Bankar A, Pettit KM, Shatzel J, Lucchesi A, García-Gutiérrez V, et al. VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-00992
BibTeX
@article{Kuykendall2026,
author = {Kuykendall, Andrew T and Bankar, Aniket and Pettit, Kristen M and Shatzel, Joseph and Lucchesi, Alessandro and García-Gutiérrez, Valentín and Mayer, Jiri and Yacoub, Abdulraheem and Gill, Harinder and Sasca, Daniel and Scandura, Joseph M and Kremyanskaya, Marina and Ross, David M and Palandri, Francesca and Fox, Maria Laura and Vannucchi, Alessandro Maria and Haque, Tamanna and Koschmieder, Steffen and Kiladjian, Jean-Jacques and Oyuela, Pedro and Dinh, Phillip and Xiao, Jie and Valone, Frank H and Gupta, Suneel and Khanna, Sarita and Molina, Arturo and Pemmaraju, Naveen and VERIFY Investigators, VERIFY Investigators},
title = {VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy},
journal = {Journal of Clinical Oncology},
year = {2026},
doi = {10.1200/jco-26-00992}
}
EUVIMED